Sepsis remains one of the most perilous acute conditions in critical care medicine. Characterized by severe systemic inflammation triggered by infection, the condition represents a leading contributor to childhood mortality worldwide, taking the lives of approximately three million children under five years of age each year. In critical scenarios where conventional interventions such as antibiotics fail to arrest the immune system’s hyperactive reaction, patients face rapidly escalating risks of multiorgan failure.
Addressing an Urgent Pediatric Critical Care Gap
Efferon, a medical technology company selected for the Startup Battlefield 200 cohort at TechCrunch Disrupt 2026, is working to alter these clinical outcomes. The company has engineered a specialized extracorporeal blood-purification device designed to curb organ failure rates and expedite recovery times in pediatric patients battling severe infection.
When a patient experiences sepsis, the immune response can quickly overwhelm bodily systems. Efferon co-founder and chief executive officer Dima Romashin illustrates the physiological crisis through the analogy of an uncontrolled blaze. In this comparison, endotoxins act as the flames while inflammatory cytokines represent the spreading smoke. While conventional therapies and standard filtering units often struggle to clear both elements simultaneously, Efferon has developed an absorption mechanism engineered to remove both endotoxins and cytokines concurrently.
Physiological Customization With Efferon NEO
Although the company produces absorption hardware for adult applications, its pediatric-focused cartridge, Efferon NEO, represents a focused effort to serve a particularly vulnerable demographic. Young children have a dramatically lower circulating blood volume compared to adults, making adult-sized filtering systems unsuitable or risky. Consequently, pediatric patients require extracorporeal systems engineered specifically around their distinct physiology.
Efferon NEO addresses this requirement directly. In April, the device obtained CE mark certification, marking Europe’s regulatory clearance and establishing it as the first multimodal blood-purification device explicitly engineered to treat pediatric sepsis.
International Deployment and Commercial Trajectory
The device is currently deployed within pediatric intensive care units across 30 nations, including facilities in Europe, Saudi Arabia, and Thailand. Building on its European regulatory foundation and international clinical footprint, Efferon is now assembling documentation to file for clearance with the United States Food and Drug Administration.
Financially, the company is progressing toward reaching $2 million in annualized revenue by the end of 2026. The foundational technology behind the adsorption systems originated in academic research conducted by scientists at Moscow State University, including co-founder Ivan Bessonov. Romashin, an experienced entrepreneur, stepped into the chief executive role earlier this year to oversee global commercialization, operational scale, and regulatory expansion.
While acknowledging that medtech commercialization follows a distinct trajectory from fast-moving software and artificial intelligence enterprises, Efferon emphasizes clinical survival as its primary benchmark, measuring overall progress by the number of young patients successfully discharged from intensive care.
